Abbott to Split Into Two Separate Companies, Reports Q3 Sales Rise 13 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Abbott today announced that it will split into two separate, publicly-traded companies — one focused on diversified medical products and the other on research-based pharmaceuticals.

The diversified medical products business, which includes the branded generic pharmaceutical, medical devices, diagnostics (including molecular diagnostics), and nutritional businesses, will retain the Abbott name. These businesses combined bring in annual revenues of roughly $22 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.